GenBank (Release 140, feb 2004)

1630 100 0.0
P_AAF44256 Human PRO1387 (UNQ722) nucleotide sequence SEQ ID NO:421. 630 bp, cDNA, PAT 02-APR-2001
ACCESSION P_AAF44256
KEYWORDS GENESEQ; Human; secreted and transmembrane protein; PRO; cytostatic; cell death; cancer; chromosomal mapping; gene mapping; tissue typing; diagnostic assay; patent; patentdb (v200408, 15-APR-2004).
SOURCE Homo sapiens.
ORGANISM Homo sapiens.
REFERENCE 1 (bases 1 to 1630)
AUTHORS Ashkenazi,A.J., Baker,K.P., Botstein,D., Desnoyers,L., Eaton,D.L. Ferrara,N., Fong,S., Gerber,H., Gerritsen,M.E., Goddard,A., Godowski,P.J. Grimaldi,C.J., Gurney,A.L., Kljavin,I.J., Napier,M.A., Pan,J., Paoni,N.F. Roy,M.A., Stewart,T.A., Tumas,D., Watanabe,C.K., Williams,P.M., Wood,W.I. Zhang,Z.
TITLE PRO polynucleotides used to produce polypeptides used to target bioactive molecules such as toxins, radiolabels or antibodies, to specific cells, to cause targeted cell death.
JOURNAL Patent: WO200073454-A1; Filing Date: 30-MAR-2000; 2000WO-US008439; Publication Date: 07-DEC-2000; Priority: 02-JUN-1999; 99WO-US012252. 23-JUN-1999; 99US-0141037P. 07-JUL-1999; 99US-0143048P. 20-JUL-1999; 99US-0144758P. 26-JUL-1999; 99US-0145698P. 28-JUL-1999; 99US-0146222P. 17-AUG-1999; 99US-0149396P. 15-SEP-1999; 99WO-US021090. 15-SEP-1999; 99WO-US021547. 08-OCT-1999; 99US-0158663P. 30-NOV-1999; 99WO-US028313. 01-DEC-1999; 99WO-US028301. 16-DEC-1999; 99WO-US030095. 20-DEC-1999; 99WO-US030911. 05-JAN-2000; 2000WO-US000219. 06-JAN-2000; 2000WO-US000376. 11-FEB-2000; 2000WO-US003565. 18-FEB-2000; 2000WO-US004341. 22-FEB-2000; 2000WO-US004414. 24-FEB-2000; 2000WO-US004914. 24-FEB-2000; 2000WO-US005004. 02-MAR-2000; 2000WO-US005841. 15-MAR-2000; 2000WO-US006884. 20-MAR-2000; 2000WO-US007377; Assignee: (GETH) GENENTECH INC; Cross Reference: WPI; 2001-032160/04. P-PSDB; AAB65287; Patent Format: Claim 2; Fig 303; 935pp; English.
COMMENT The present invention describes human secreted and transmembrane PRO proteins. The PRO proteins have cytostatic activity. The PRO proteins can be used for targeted delivery of bioactive molecules, such as toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide sequences, and their fragments, can be used as hybridisation probes, in chromosomal and gene mapping, and in the generation of anti-sense RNA and DNA. They may also be used to produce transgenic animals which are used to develop and screen therapeutically useful reagents. The PRO nucleotide and protein sequence can be used for tissue typing and in treating cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to AAF44470 represent PCR primers and hybridisation probes used in the isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to AAB65300 represent human PRO polynucleotide and protein sequences given in the exemplification of the present invention
FEATURES Location/Qualifiers
BASE COUNT 425 a 369 c 452 g 384 t
ORIGIN

1630 100 0.0

P_AAS21503 Human cDNA sequence encoding for PRO1387 polypeptide. 630 bp, cDNA, PAT 24-OCT-2001

ACCESSION P_AAS21503

KEYWORDS GENESEQ; Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte; A-peptide; factor VIIA; gene therapy; patent; patentdb (v200408, 15-APR-2004).

SOURCE Homo sapiens.

ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 1630)

AUTHORS Baker,K.P., Beresini,M., Deforge,L., Desnoyers,L., Filvaroff,E., Gao,W. Gerritsen,M.E., Goddard,A., Godowski,P.J., Gurney,A.L., Sherwood,S. Smith,V., Stewart,T.A., Tumas,D., Watanabe,C.K., Wood,W.I., Zhang,Z.

TITLE Isolated , secretory and transmembrane PRO polypeptide used to detect other PRO polypeptides, link bioactive molecules to cells expressing PRO polypeptides, and detect the presence of mammalian tumors e.g. lung, breast, prostate, cervical.

JOURNAL Patent: WO200140466-A2; Filing Date: 01-DEC-2000; 2000WO-US032678; Publication Date: 07-JUN-2001; Priority: 01-DEC-1999; 99WO-US028301. 01-DEC-1999; 99WO-US028634. 02-DEC-1999; 99WO-US028551. 02-DEC-1999; 99WO-US028564. 02-DEC-1999; 99WO-US028565. 09-DEC-1999; 99US-0170262P. 16-DEC-1999; 99WO-US030095. 20-DEC-1999; 99WO-US030911. 20-DEC-1999; 99WO-US030999. 30-DEC-1999; 99WO-US031243. 30-DEC-1999; 99WO-US031274. 05-JAN-2000; 2000WO-US000219. 06-JAN-2000; 2000WO-US000277. 06-JAN-2000; 2000WO-US000376. 11-FEB-2000; 2000WO-US003565. 18-FEB-2000; 2000WO-US004341. 18-FEB-2000; 2000WO-US004342. 22-FEB-2000; 2000WO-US004414. 24-FEB-2000; 2000WO-US004914. 24-FEB-2000; 2000WO-US005004. 01-MAR-2000; 2000WO-US005601. 02-MAR-2000; 2000WO-US005841. 03-MAR-2000; 2000US-0187202P. 10-MAR-2000; 2000WO-US006319. 15-MAR-2000; 2000WO-US006884. 20-MAR-2000; 2000WO-US007377. 21-MAR-2000; 2000WO-US007532. 30-MAR-2000; 2000WO-US008439. 17-MAY-2000; 2000WO-US013705. 22-MAY-2000; 2000WO-US014042. 30-MAY-2000; 2000WO-US014941. 02-JUN-2000; 2000WO-US015264. 05-JUN-2000; 2000US-0209832P. 28-JUL-2000; 2000WO-US020710. 11-AUG-2000; 2000WO-US022031. 23-AUG-2000; 2000WO-US023522. 24-AUG-2000; 2000WO-US023328. 08-NOV-2000; 2000WO-US030952. 10-NOV-2000; 2000WO-US030873; Assignee: (GETH) GENENTECH INC; Cross Reference: WPI; 2001-408281/43. P-PSDB; AAU12431; Patent Format: Claim 3; Fig 519; 813pp; English.

COMMENT AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO polypeptides. The PRO polypeptides are useful to detect other PRO polypeptides, to link bioactive molecules to cells expressing PRO polypeptides, to modulate biological activities of cells expressing PRO polypeptides, and to detect the presence of mammalian lung, colon, breast, prostate, rectal, cervical or liver tumours by comparing PRO polypeptide expression in a cell sample to that in a control sample. Some of the 275 sequences are also useful to stimulate the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or differentiation of chondrocytes, the proliferation or gene expression in pericyte cells, the release of proteoglycans from cartilage, the proliferation of inner ear utricular supporting cells or of T-lymphocytes, the release of a cytokine from peripheral blood

monocytes (PBMCs), or the proliferation of endothelial cells. Some of the PRO polypeptides may modulate glucose or free fatty acid uptake by skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide to factor VIIA. The PRO polypeptides can be used in assays to identify molecules involved in binding interactions. The polynucleotides encoding PRO polypeptides can be used to generate probes, antisense RNA/DNA, transgenic or knock out animals and can be used in gene therapy

FEATURES Location/Qualifiers
BASE COUNT 425 a 369 c 452 g 384 t
ORIGIN

1630 100 0.0
P_AAZ65110 Membrane-bound protein PRO1387 encoding cDNA. 630 bp, cDNA, PAT 05-APR-2000
ACCESSION P_AAZ65110
KEYWORDS GENESEQ; Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand; pharmaceutical; receptor immunoadhesin; gene mapping; patent; patentdb (v200408, 15-APR-2004).
SOURCE Homo sapiens.
ORGANISM Homo sapiens.
REFERENCE 1 (bases 1 to 1630)
AUTHORS Baker,K., Chen,J., Goddard,A., Gurney,A.L., Smith,V., Watanabe,C.K. Wood,W.I., Yuan,J.
TITLE Membrane-bound proteins and related nucleotide sequences.
JOURNAL Patent: WO9963088-A2; Filing Date: 02-JUN-1999; 99WO-US012252; Publication Date: 09-DEC-1999; Priority: 02-JUN-1998;
98US-0087607P. 02-JUN-1998; 98US-0087609P. 02-JUN-1998;
98US-0087759P. 03-JUN-1998; 98US-0087827P. 04-JUN-1998;
98US-0088021P. 04-JUN-1998; 98US-0088025P. 04-JUN-1998;
98US-0088028P. 04-JUN-1998; 98US-0088029P. 04-JUN-1998;
98US-0088030P. 04-JUN-1998; 98US-0088033P. 04-JUN-1998;
98US-0088326P. 05-JUN-1998; 98US-0088167P. 05-JUN-1998;
98US-0088202P. 05-JUN-1998; 98US-0088212P. 05-JUN-1998;
98US-0088217P. 09-JUN-1998; 98US-0088655P. 10-JUN-1998;
98US-0088722P. 10-JUN-1998; 98US-0088730P. 10-JUN-1998;
98US-0088734P. 10-JUN-1998; 98US-0088738P. 10-JUN-1998;
98US-0088740P. 10-JUN-1998; 98US-0088741P. 10-JUN-1998;
98US-0088742P. 10-JUN-1998; 98US-0088810P. 10-JUN-1998;
98US-0088811P. 10-JUN-1998; 98US-0088824P. 10-JUN-1998;
98US-0088825P. 10-JUN-1998; 98US-0088826P. 11-JUN-1998;
98US-0088858P. 11-JUN-1998; 98US-0088861P. 11-JUN-1998;
98US-0088863P. 11-JUN-1998; 98US-0088876P. 12-JUN-1998;
98US-0089090P. 12-JUN-1998; 98US-0089105P. 16-JUN-1998;
98US-0089440P. 16-JUN-1998; 98US-0089512P. 16-JUN-1998;
98US-0089514P. 17-JUN-1998; 98US-0089532P. 17-JUN-1998;
98US-0089538P. 17-JUN-1998; 98US-0089598P. 17-JUN-1998;
98US-0089599P. 17-JUN-1998; 98US-0089600P. 17-JUN-1998;
98US-0089653P. 18-JUN-1998; 98US-0089801P. 18-JUN-1998;
98US-0089907P. 18-JUN-1998; 98US-0089908P. 19-JUN-1998;
98US-0089947P. 19-JUN-1998; 98US-0089948P. 19-JUN-1998;
98US-0089952P. 22-JUN-1998; 98US-0090246P. 22-JUN-1998;
98US-0090252P. 22-JUN-1998; 98US-0090254P. 23-JUN-1998;
98US-0090349P. 23-JUN-1998; 98US-0090355P. 24-JUN-1998;
98US-0090429P. 24-JUN-1998; 98US-0090431P. 24-JUN-1998;
98US-0090435P. 24-JUN-1998; 98US-0090444P. 24-JUN-1998;
98US-0090445P. 24-JUN-1998; 98US-0090461P. 24-JUN-1998;

98US-0090472P. 24-JUN-1998; 98US-0090535P. 24-JUN-1998;
98US-0090538P. 24-JUN-1998; 98US-0090540P. 24-JUN-1998;
98US-0090557P. 25-JUN-1998; 98US-0090676P. 25-JUN-1998;
98US-0090678P. 25-JUN-1998; 98US-0090688P. 25-JUN-1998;
98US-0090690P. 25-JUN-1998; 98US-0090691P. 25-JUN-1998;
98US-0090694P. 25-JUN-1998; 98US-0090695P. 25-JUN-1998;
98US-0090696P. 26-JUN-1998; 98US-0090862P. 26-JUN-1998;
98US-0090863P. 01-JUL-1998; 98US-0091358P. 01-JUL-1998;
98US-0091360P. 02-JUL-1998; 98US-0091478P. 02-JUL-1998;
98US-0091486P. 02-JUL-1998; 98US-0091519P. 02-JUL-1998;
98US-0091544P. 02-JUL-1998; 98US-0091626P. 02-JUL-1998;
98US-0091628P. 02-JUL-1998; 98US-0091633P. 02-JUL-1998;
98US-0091646P. 02-JUL-1998; 98US-0091673P. 07-JUL-1998;
98US-0091978P. 07-JUL-1998; 98US-0091982P. 09-JUL-1998;
98US-0092182P. 10-JUL-1998; 98US-0092472P. 20-JUL-1998;
98US-0093339P. 30-JUL-1998; 98US-0094651P. 04-AUG-1998;
98US-0095282P. 04-AUG-1998; 98US-0095285P. 04-AUG-1998;
98US-0095301P. 04-AUG-1998; 98US-0095302P. 04-AUG-1998;
98US-0095318P. 04-AUG-1998; 98US-0095321P. 04-AUG-1998;
98US-0095325P. 10-AUG-1998; 98US-0095916P. 10-AUG-1998;
98US-0095929P. 10-AUG-1998; 98US-0096012P. 11-AUG-1998;
98US-0096143P. 11-AUG-1998; 98US-0096146P. 12-AUG-1998;
98US-0096329P. 17-AUG-1998; 98US-0096757P. 17-AUG-1998;
98US-0096766P. 17-AUG-1998; 98US-0096768P. 17-AUG-1998;
98US-0096773P. 17-AUG-1998; 98US-0096791P. 17-AUG-1998;
98US-0096867P. 17-AUG-1998; 98US-0096891P. 17-AUG-1998;
98US-0096894P. 17-AUG-1998; 98US-0096895P. 17-AUG-1998;
98US-0096897P. 18-AUG-1998; 98US-0096949P. 18-AUG-1998;
98US-0096950P. 18-AUG-1998; 98US-0096959P. 18-AUG-1998;
98US-0096960P. 18-AUG-1998; 98US-0097022P. 19-AUG-1998;
98US-0097141P. 20-AUG-1998; 98US-0097218P. 24-AUG-1998;
98US-0097661P. 26-AUG-1998; 98US-0097951P. 26-AUG-1998;
98US-0097952P. 26-AUG-1998; 98US-0097954P. 26-AUG-1998;
98US-0097955P. 26-AUG-1998; 98US-0097971P. 26-AUG-1998;
98US-0097974P. 26-AUG-1998; 98US-0097978P. 26-AUG-1998;
98US-0097979P. 26-AUG-1998; 98US-0097986P. 26-AUG-1998;
98US-0098014P. 31-AUG-1998; 98US-0098525P. 16-SEP-1998;
98US-0100634P. 12-JAN-1999; 99US-0115565P; Assignee: (GETH)
GENENTECH INC; Cross Reference: WPI; 2000-072883/06. P-PSDB;
AAY66764; Patent Format: Claim 2; Fig 303; 822pp; English.

COMMENT The invention provides membrane-bound PRO polypeptides and polynucleotides encoding them. The PRO sequences of the invention were identified based on extracellular domain homology screening. The PRO sequences have homology with proteins including LDL receptors, TIE ligands and various enzymes. The membrane-bound proteins and receptor molecules are useful as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be used as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The PRO encoding sequences are useful as hybridization probes, in chromosome and gene mapping and in the generation of antisense RNA and DNA. PRO nucleic acid sequences will also be useful for the preparation of PRO polypeptides, especially by recombinant techniques

FEATURES Location/Qualifiers

BASE COUNT 425 a 369 c 452 g 384 t

ORIGIN

1630 100 0.0
P_AAA77683 Human PRO1387 cDNA sequence SEQ ID NO:219. 630 bp, cDNA, PAT 07-NOV-2000
ACCESSION P_AAA77683
KEYWORDS GENESEQ; Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation; diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy; angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic; cytostatic; gene therapy; vaccine; patent; patentdb (v200408, 15-APR-2004).
SOURCE Homo sapiens.
ORGANISM Homo sapiens.
REFERENCE 1 (bases 1 to 1630)
AUTHORS Ashkenazi,A.J., Baker,K.P., Ferrara,N., Gerber,H., Hillan,K.J. Goddard,A., Godowski,P.J., Gurney,A.L., Klein,R.D., Kuo,S.S., Paoni,N.F. Smith,V., Watanabe,C.K., Williams,P.M., Wood,W.I.
TITLE Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating diagnosing a cardiovascular, endothelial or angiogenic disorders in mammals.
JOURNAL Patent: WO200032221-A2; Filing Date: 30-NOV-1999; 99WO-US028313; Publication Date: 08-JUN-2000; Priority: 01-DEC-1998; 98WO-US025108. 16-DEC-1998; 98US-0112850P. 12-JAN-1999; 99US-0115554P. 08-MAR-1999; 99WO-US005028. 12-MAR-1999; 99US-0123957P. 28-APR-1999; 99US-0131445P. 14-MAY-1999; 99US-0134287P. 02-JUN-1999; 99WO-US012252. 23-JUN-1999; 99US-0141037P. 20-JUL-1999; 99US-0144758P. 26-JUL-1999; 99US-0145698P. 01-SEP-1999; 99WO-US020111. 08-SEP-1999; 99WO-US020594. 13-SEP-1999; 99WO-US020944. 15-SEP-1999; 99WO-US021090. 15-SEP-1999; 99WO-US021547. 05-OCT-1999; 99WO-US023089. 29-OCT-1999; 99US-0162506P; Assignee: (GETH) GENENTECH INC; Cross Reference: WPI; 2000-412154/35. P-PSDB; AAB24433; Patent Format: Claim 61; Fig 91; 315pp; English.
COMMENT The present invention describes nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating diagnosing a cardiovascular, endothelial or angiogenic disorder in mammals by modulating cell proliferation, angiogenesis and cardiovascularisation, and for identifying agonists and antagonists of these processes. The nucleic acids and the proteins they encode may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PRO expression such as cardiovascular, endothelial or angiogenic disorders in mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For example, the nucleic acids (NCs) and vectors containing them and the PRO polypeptide may be used to treat disorders associated with decreased PRO expression. AAA77510 to AAA77721 and AAB24388 to AAB24435 represent nucleotide and protein sequences used in the exemplification of the present invention
FEATURES Location/Qualifiers
BASE COUNT 425 a 369 c 452 g 384 t
ORIGIN

1621 100 0.0
P_AAC58619 Human PRO1387 protein UNQ722 encoding cDNA SEQ ID NO:186. 621 bp, cDNA, PAT 29-JAN-2001
ACCESSION P_AAC58619
KEYWORDS GENESEQ; Human; immune related disease; diagnosis; antiinflammatory;

cardiant; dermatological; antiarthritic; antirheumatic; immunosuppressive; haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective; antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic; antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis; osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis; idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis; systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus; autoimmune thrombocytopaenia; immune-mediated renal disease; demyelinating disease; hepatobiliary disease; Whipple's disease; inflammatory bowel disease; gluten-sensitive enteropathy; autoimmune disease; immune-mediated skin disease; allergic disease; immunological disease; transplantation associated disease; graft rejection; graft-versus-host-disease; patent; patentdb (v200408, 15-APR-2004).

SOURCE Homo sapiens.
ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 1621)
AUTHORS Ashkenazi,A.J., Baker,K.P., Goddard,A., Gurney,A.L., Hebert,C., Henzel,W. Kabakoff,R.C., Lu,Y., Pan,J., Pennica,D., Shelton,D.L., Smith,V. Stewart,T.A., Tumas,D., Watanabe,C.K., Wood,W.I., Yan,M.
TITLE Sixty four PRO polypeptides, useful in the diagnosis and treatment of immune related disorders, e.g. systemic lupus erythematosis, rheumatoid arthritis, osteoarthritis, thyroiditis and diabetes mellitus.
JOURNAL Patent: WO200053758-A2; Filing Date: 02-MAR-2000; 2000WO-US005841; Publication Date: 14-SEP-2000; Priority: 08-MAR-1999; 99WO-US005028. 10-MAR-1999; 99US-0123618P. 12-MAR-1999; 99US-0123957P. 23-MAR-1999; 99US-0125775P. 12-APR-1999; 99US-0128849P. 20-APR-1999; 99WO-US008615. 28-APR-1999; 99US-0131445P. 04-MAY-1999; 99US-0132371P. 14-MAY-1999; 99US-0134287P. 02-JUN-1999; 99WO-US012252. 23-JUN-1999; 99US-0141037P. 20-JUL-1999; 99US-0144758P. 26-JUL-1999; 99US-0145698P. 28-JUL-1999; 99US-0146222P. 01-SEP-1999; 99WO-US020111. 08-SEP-1999; 99WO-US020594. 13-SEP-1999; 99WO-US020944. 15-SEP-1999; 99WO-US021090. 15-SEP-1999; 99WO-US021547. 05-OCT-1999; 99WO-US023089. 29-OCT-1999; 99US-0162506P. 29-NOV-1999; 99WO-US028214. 30-NOV-1999; 99WO-US028313. 30-NOV-1999; 99WO-US028409. 01-DEC-1999; 99WO-US028301. 01-DEC-1999; 99WO-US028634. 02-DEC-1999; 99WO-US028551. 02-DEC-1999; 99WO-US028564. 02-DEC-1999; 99WO-US028565. 16-DEC-1999; 99WO-US030095. 20-DEC-1999; 99WO-US030999. 30-DEC-1999; 99WO-US031274. 05-JAN-2000; 2000WO-US000219. 06-JAN-2000; 2000WO-US000277. 06-JAN-2000; 2000WO-US000376. 11-FEB-2000; 2000WO-US003565. 18-FEB-2000; 2000WO-US004341. 18-FEB-2000; 2000WO-US004342. 22-FEB-2000; 2000WO-US004414; Assignee: (GETH) GENENTECH INC; Cross Reference: WPI; 2000-572271/53. P-PSDB; AAB33454; Patent Format: Claim 23; Fig 81; 309pp; English.

COMMENT The present invention describes sixty four human PRO proteins which can be used in the treatment of immune related diseases. The human PRO proteins, anti-PRO antibodies, agonists and antagonists are useful for treating and diagnosing immune related disorders. The disorders are selected from systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, idiopathic inflammatory

myopathies, Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central and peripheral nervous systems, hepatobiliary diseases, inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune or immune-mediated skin diseases, allergic diseases, immunological diseases of the lung, and transplantation associated diseases including graft rejection and graft-versus-host-disease. AAC58397 to AAC58578 represent PCR primers and hybridisation probes used in the isolation of human PRO sequences. AAC58579 to AAC58642 and AAB33414 to AAB33477 represent human PRO polynucleotide and protein sequences given in the exemplification of the present invention

FEATURES Location/Qualifiers
BASE COUNT 424 a 366 c 448 g 383 t
ORIGIN

1620 100 0.0
P_AAA27133 Human inflammation associated cDNA #11. 751 bp, cDNA, PAT 11-SEP-2000
ACCESSION P_AAA27133
KEYWORDS GENESEQ; Inflammation; rheumatoid arthritis; Crohn's disease; asthma; multiple sclerosis; allergy; AIDS; diabetes mellitus; antiinflammatory; gene therapy; human; patent; patentdb (v200408, 15-APR-2004).
SOURCE Homo sapiens.
ORGANISM Homo sapiens.
REFERENCE 1 (bases 1 to 1751)
AUTHORS Walker,M.G., Volkmuth,W., Klingler,T.M.
TITLE New human inflammation-associated polypeptide useful for diagnosis, prevention and treatment of inflammatory diseases comprises product of gene coexpressed with e.g. CD16, L-selectin and IP-30.
JOURNAL Patent: WO200029574-A2; Filing Date: 04-NOV-1999; 99WO-US026234; Publication Date: 25-MAY-2000; Priority: 18-NOV-1998; 98US-00195292; Assignee: (INCY-) INCYTE PHARM INC; Cross Reference: WPI; 2000-387787/33. P-PSDB; AAY94452; Patent Format: Claim 2; Page 37-38; 43pp; English.
COMMENT Eleven novel inflammation-associated genes have been identified in cDNA libraries from various tissues. The genes were selected according to their coexpression with the known inflammation genes, CD16, L-selectin, Src-like adapter protein, IP-30, superoxidase homoenzyme subunits, alpha- 1-antitrypsin, Clq-A, 5-lipoxygenase activating protein and SRC family tyrosine kinase. The novel polynucleotides may be used in hybridization assays to diagnose a disease or condition associated with altered expression of the inflammation genes. Antibodies against the genes may be useful in compositions for the diagnosis and treatment of such diseases associated with inflammation including rheumatoid arthritis, Crohn's disease, multiple sclerosis, AIDS, diabetes mellitus, asthma and allergy. Additionally the polynucleotides of the invention may be used for gene therapy. The present sequence is human inflammation associated cDNA #11, derived from Incyte Clone 3507924
FEATURES Location/Qualifiers
CDS 186..1370
/*tag= a
/product= "inflammation associated protein #11"
BASE COUNT 454 a 396 c 479 g 422 t

ORIGIN

1619 100 0.0
P_AAI59802 Human polynucleotide SEQ ID NO 3791. 876 bp, cDNA, PAT 22-OCT-2001
ACCESSION P_AAI59802
KEYWORDS GENESEQ; Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer; peripheral nervous system; neuropathy; central nervous system; CNS; Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic; amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic; chemokinetic; thrombolytic; drug screening; arthritis; inflammation; leukaemia; patent; patentdb (v200408, 15-APR-2004).
SOURCE Homo sapiens.
ORGANISM Homo sapiens.
REFERENCE 1 (bases 1 to 1876)
AUTHORS Tang,Y.T., Liu,C., Asundi,V., Chen,R., Ma,Y., Qian,X.B., Ren,F., Wang,D. Wang,J., Wang,Z., Wehrman,T., Xu,C., Xue,A.J., Yang,Y., Zhang,J., Zhao,Q.A. Zhou,P., Goodrich,R., Drmanac,R.T.
TITLE Novel nucleic acids and polypeptides, useful for treating disorders such as central nervous system injuries.
JOURNAL Patent: WO200153312-A1; Filing Date: 26-DEC-2000; 2000WO-US034263; Publication Date: 26-JUL-2001; Priority: 23-DEC-1999; 99US-00471275. 21-JAN-2000; 2000US-00488725. 25-APR-2000; 2000US-00552317. 20-JUN-2000; 2000US-00598042. 19-JUL-2000; 2000US-00620312. 03-AUG-2000; 2000US-00653450. 14-SEP-2000; 2000US-00662191. 19-OCT-2000; 2000US-00693036. 29-NOV-2000; 2000US-00727344; Assignee: (HYSE-) HYSEQ INC; Cross Reference: WPI; 2001-442253/47. P-PSDB; AAM40646; Patent Format: Claim 1; SEQ ID NO 3791; 10078pp; English.
COMMENT The invention relates to human nucleic acids (AAI57798-AAI61369) and the encoded polypeptides (AAM38642-AAM42213) with nootropic, immunosuppressant and cytostatic activity. The polynucleotides are useful in gene therapy. A composition containing a polypeptide or polynucleotide of the invention may be used to treat diseases of the peripheral nervous system, such as peripheral nervous injuries, peripheral neuropathy and localised neuropathies and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager Syndrome. Other uses include the utilisation of the activities such as: Immune system suppression, Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, cancer diagnosis and therapy, drug screening, assays for receptor activity, arthritis and inflammation, leukaemias and C.N.S disorders. Note: The sequence data for this patent did not form part of the printed specification
FEATURES Location/Qualifiers
BASE COUNT 493 a 401 c 524 g 458 t
ORIGIN

1505 100 0.0
P_AAZ52456 HTRM clone 319415 DNA sequence. 649 bp, DNA, PAT 24-FEB-2000
ACCESSION P_AAZ52456
KEYWORDS GENESEQ; HTRM; human transcriptional regulatory molecule; arteriosclerosis; AIDS; arteriosclerosis; cirrhosis; cancer; leukaemia; diabetes mellitus; ss; Addison's disease; multiple sclerosis; rheumatoid arthritis; infection; trauma; myasthenia gravis; adenocarcinoma; immune disorder; treatment; patent; patentdb

(v200408, 15-APR-2004).
SOURCE Homo sapiens.
ORGANISM Homo sapiens.
REFERENCE 1 (bases 1 to 1649)
AUTHORS Hillman,J.L., Bandman,O., Lal,P., Yue,H., Reddy,R., Tang,Y.T. Gerstin,E.H., Patterson,C., Baughn,M.R., Azimzai,Y., Lu,D.A.M.
TITLE New peptides useful for diagnosis, prevention and treatment of cancer and immune disorders.
JOURNAL Patent: WO9957144-A2; Filing Date: 04-MAY-1999; 99WO-US009935; Publication Date: 11-NOV-1999; Priority: 05-MAY-1998; 98US-0084254P. 07-AUG-1998; 98US-0095827P. 02-OCT-1998; 98US-0102745P; Assignee: (INCY-) INCYTE PHARM INC; Cross Reference: WPI; 2000-052941/04. P-PSDB; AAY73371; Patent Format: Claim 9; Page 179; 193pp; English.
COMMENT AAZ52410-Z52474 are human transcriptional regulator molecule (HTRM) nucleotide sequences. The HTRM protein and nucleotide sequences are useful for preventing or treating disorders associated with decreased expression or activity of HTRM which include cell proliferative disorders such as arteriosclerosis and cirrhosis; cancers including adenocarcinoma and leukaemia; immune disorders such as AIDS, Addison's disease, diabetes mellitus, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and myasthenia gravis; infections and trauma. Antagonists of the HTRM polypeptides are useful for treating or preventing disorders associated with increased expression or activity of HTRMs. HTRM polypeptides, their immunogenic fragments or oligopeptides are useful for screening libraries of compounds in drug screening techniques. Polynucleotides encoding HTRM are useful for blocking the transcription of mRNA and regulating gene function by modulating the activity of HTRM. Vectors expressing HTRM or agonists can also be used to prevent or treat disorder associated with decreased HTRM expression. Antibodies which specifically bind HTRM and polynucleotides encoding HTRM are useful for diagnosing disorders associated with the expression of HTRM, particularly in assays that detect the expression of HTRM. Nucleotide sequences encoding HTRM may be useful to generate hybridization probes useful in mapping the naturally occurring genomic sequence and to detect differences in gene sequences among normal, carrier and affected individuals. Using diagnostic assays, cancer can be detected prior to the appearance of clinical symptoms and thereby progression of cancer can be prevented by aggressive treatment or preventive measures
FEATURES Location/Qualifiers
BASE COUNT 433 a 372 c 455 g 389 t
ORIGIN

1393 100 0.0
P_AAI58016 Human polynucleotide SEQ ID NO 219. 473 bp, cDNA, PAT 22-OCT-2001
ACCESSION P_AAI58016
KEYWORDS GENESEQ; Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer; peripheral nervous system; neuropathy; central nervous system; CNS; Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic; amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic; chemokinetic; thrombolytic; drug screening; arthritis; inflammation; leukaemia; patent; patentdb (v200408, 15-APR-2004).
SOURCE Homo sapiens.

ORGANISM Homo sapiens.
REFERENCE 1 (bases 1 to 1473)
AUTHORS Tang,Y.T., Liu,C., Asundi,V., Chen,R., Ma,Y., Qian,X.B., Ren,F., Wang,D. Wang,J., Wang,Z., Wehrman,T., Xu,C., Xue,A.J., Yang,Y., Zhang,J., Zhao,Q.A. Zhou,P., Goodrich,R., Drmanac,R.T.
TITLE Novel nucleic acids and polypeptides, useful for treating disorders such as central nervous system injuries.
JOURNAL Patent: WO200153312-A1; Filing Date: 26-DEC-2000; 2000WO-US034263; Publication Date: 26-JUL-2001; Priority: 23-DEC-1999; 99US-00471275. 21-JAN-2000; 2000US-00488725. 25-APR-2000; 2000US-00552317. 20-JUN-2000; 2000US-00598042. 19-JUL-2000; 2000US-00620312. 03-AUG-2000; 2000US-00653450. 14-SEP-2000; 2000US-00662191. 19-OCT-2000; 2000US-00693036. 29-NOV-2000; 2000US-00727344; Assignee: (HYSE-) HYSEQ INC; Cross Reference: WPI; 2001-442253/47. P-PSDB; AAM38860; Patent Format: Claim 1; SEQ ID NO 219; 10078pp; English.
COMMENT The invention relates to human nucleic acids (AAI57798-AAI61369) and the encoded polypeptides (AAM38642-AAM42213) with nootropic, immunosuppressant and cytostatic activity. The polynucleotides are useful in gene therapy. A composition containing a polypeptide or polynucleotide of the invention may be used to treat diseases of the peripheral nervous system, such as peripheral nervous injuries, peripheral neuropathy and localised neuropathies and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager Syndrome. Other uses include the utilisation of the activities such as: Immune system suppression, Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, cancer diagnosis and therapy, drug screening, assays for receptor activity, arthritis and inflammation, leukaemias and C.N.S disorders. Note: The sequence data for this patent did not form part of the printed specification
FEATURES Location/Qualifiers
BASE COUNT 383 a 341 c 394 g 355 t
ORIGIN

(A)

P2730P1C46

BLAST RESULTS #1

Wed Nov 21 13:57:28 2001 [BLASTN 2.2.1 [Jul-12-2001], NCBI]
/home/ruby/va/Molbio/carpenda/tempblast/ss.DNA68872 (1630 bp)

Sequences producing High-scoring Segment Pairs:		Frame	Score	Match	Pct	E-val
1	P_AAF44256 Human PRO1387 (UNQ722) nucleotide sequen	+	1630	1630	100	0.0
2	P_AAS21503 Human cDNA sequence encoding for PRO1387	+	1630	1630	100	0.0
3	P_AAZ65110 Membrane-bound protein PRO1387 encoding	+	1630	1630	100	0.0
4	P_AAA77683 Human PRO1387 cDNA sequence SEQ ID NO:21	+	1630	1630	100	0.0
5	P_AAC58619 Human PRO1387 protein UNQ722 encoding cD	+	1621	1621	100	0.0
6	P_AAA27133 Human inflammation associated cDNA #11.	+	1620	1620	100	0.0
7	P_AAI59802 Human polynucleotide SEQ ID NO 3791. cD	+	1616	1619	100	0.0
8	P_AAZ52456 HTRM clone 319415 DNA sequence.	+	1505	1505	100	0.0
9	P_AAI58016 Human polynucleotide SEQ ID NO 219. cDN	+	1383	1393	100	0.0

>1 P_AAF44256 Human PRO1387 (UNQ722) nucleotide sequence SEQ ID NO:421. (1630 bp) [1 seg]
Score = 1630 (3231 bits), Expect = 0.0
Identities = 1630/1630 (100%), at 1,1-1630,1630, Strand +/+

```
ss.DNA68872     1 CGGCTCGAGTGCAGCTGTGGGGAGATTTCAGTGCATTGCCTCCCCTGGGTGCTCTTCATC
                  ************************************************************
P_AAF44256      1 CGGCTCGAGTGCAGCTGTGGGGAGATTTCAGTGCATTGCCTCCCCTGGGTGCTCTTCATC

ss.DNA68872    61 TTGGATTTGAAAGTTGAGAGCAGCATGTTTTGCCCACTGAAACTCATCCTGCTGCCAGTG
                  ************************************************************
P_AAF44256     61 TTGGATTTGAAAGTTGAGAGCAGCATGTTTTGCCCACTGAAACTCATCCTGCTGCCAGTG

ss.DNA68872   121 TTACTGGATTATTCCTTGGGCCTGAATGACTTGAATGTTTCCCCGCCTGAGCTAACAGTC
                  ************************************************************
P_AAF44256    121 TTACTGGATTATTCCTTGGGCCTGAATGACTTGAATGTTTCCCCGCCTGAGCTAACAGTC

ss.DNA68872   181 CATGTGGGTGATTCAGCTCTGATGGGATGTGTTTTCCAGAGCACAGAAGACAAATGTATA
                  ************************************************************
P_AAF44256    181 CATGTGGGTGATTCAGCTCTGATGGGATGTGTTTTCCAGAGCACAGAAGACAAATGTATA

ss.DNA68872   241 TTCAAGATAGACTGGACTCTGTCACCAGGAGAGCACGCCAAGGACGAATATGTGCTATAC
                  ************************************************************
P_AAF44256    241 TTCAAGATAGACTGGACTCTGTCACCAGGAGAGCACGCCAAGGACGAATATGTGCTATAC

ss.DNA68872   301 TATTACTCCAATCTCAGTGTGCCTATTGGGCGCTTCCAGAACCGCGTACACTTGATGGGG
                  ************************************************************
P_AAF44256    301 TATTACTCCAATCTCAGTGTGCCTATTGGGCGCTTCCAGAACCGCGTACACTTGATGGGG

ss.DNA68872   361 GACATCTTATGCAATGATGGCTCTCTCCTGCTCCAAGATGTGCAAGAGGCTGACCAGGGA
                  ************************************************************
P_AAF44256    361 GACATCTTATGCAATGATGGCTCTCTCCTGCTCCAAGATGTGCAAGAGGCTGACCAGGGA

ss.DNA68872   421 ACCTATATCTGTGAAATCCGCCTCAAAGGGGAGAGCCAGGTGTTCAAGAAGGCGGTGGTA
                  ************************************************************
P_AAF44256    421 ACCTATATCTGTGAAATCCGCCTCAAAGGGGAGAGCCAGGTGTTCAAGAAGGCGGTGGTA

ss.DNA68872   481 CTGCATGTGCTTCCAGAGGAGCCCAAAGAGCTCATGGTCCATGTGGGTGGATTGATTCAG
                  ************************************************************
P_AAF44256    481 CTGCATGTGCTTCCAGAGGAGCCCAAAGAGCTCATGGTCCATGTGGGTGGATTGATTCAG

ss.DNA68872   541 ATGGGATGTGTTTTCCAGAGCACAGAAGTGAAACACGTGACCAAGGTAGAATGGATATTT
```

```
                    ************************************************************
P_AAF44256     541  ATGGGATGTGTTTTCCAGAGCACAGAAGTGAAACACGTGACCAAGGTAGAATGGATATTT

ss.DNA68872    601  TCAGGACGGCGCGCAAAGGAGGAGATTGTATTTCGTTACTACCACAAACTCAGGATGTCT
                    ************************************************************
P_AAF44256     601  TCAGGACGGCGCGCAAAGGAGGAGATTGTATTTCGTTACTACCACAAACTCAGGATGTCT

ss.DNA68872    661  GTGGAGTACTCCCAGAGCTGGGGCCACTTCCAGAATCGTGTGAACCTGGTGGGGGACATT
                    ************************************************************
P_AAF44256     661  GTGGAGTACTCCCAGAGCTGGGGCCACTTCCAGAATCGTGTGAACCTGGTGGGGGACATT

ss.DNA68872    721  TTCCGCAATGACGGTTCCATCATGCTTCAAGGAGTGAGGGAGTCAGATGGAGGAAACTAC
                    ************************************************************
P_AAF44256     721  TTCCGCAATGACGGTTCCATCATGCTTCAAGGAGTGAGGGAGTCAGATGGAGGAAACTAC

ss.DNA68872    781  ACCTGCAGTATCCACCTAGGGAACCTGGTGTTCAAGAAAACCATTGTGCTGCATGTCAGC
                    ************************************************************
P_AAF44256     781  ACCTGCAGTATCCACCTAGGGAACCTGGTGTTCAAGAAAACCATTGTGCTGCATGTCAGC

ss.DNA68872    841  CCGGAAGAGCCTCGAACACTGGTGACCCCGGCAGCCCTGAGGCCTCTGGTCTTGGGTGGT
                    ************************************************************
P_AAF44256     841  CCGGAAGAGCCTCGAACACTGGTGACCCCGGCAGCCCTGAGGCCTCTGGTCTTGGGTGGT

ss.DNA68872    901  AATCAGTTGGTGATCATTGTGGGAATTGTCTGTGCCACAATCCTGCTGCTCCCTGTTCTG
                    ************************************************************
P_AAF44256     901  AATCAGTTGGTGATCATTGTGGGAATTGTCTGTGCCACAATCCTGCTGCTCCCTGTTCTG

ss.DNA68872    961  ATATTGATCGTGAAGAAGACCTGTGGAAATAAGAGTTCAGTGAATTCTACAGTCTTGGTG
                    ************************************************************
P_AAF44256     961  ATATTGATCGTGAAGAAGACCTGTGGAAATAAGAGTTCAGTGAATTCTACAGTCTTGGTG

ss.DNA68872   1021  AAGAACACGAAGAAGACTAATCCAGAGATAAAAGAAAAACCCTGCCATTTTGAAAGATGT
                    ************************************************************
P_AAF44256    1021  AAGAACACGAAGAAGACTAATCCAGAGATAAAAGAAAAACCCTGCCATTTTGAAAGATGT

ss.DNA68872   1081  GAAGGGGAGAAACACATTTACTCCCCAATAATTGTACGGGAGGTGATCGAGGAAGAAGAA
                    ************************************************************
P_AAF44256    1081  GAAGGGGAGAAACACATTTACTCCCCAATAATTGTACGGGAGGTGATCGAGGAAGAAGAA

ss.DNA68872   1141  CCAAGTGAAAAATCAGAGGCCACCTACATGACCATGCACCCAGTTTGGCCTTCTCTGAGG
                    ************************************************************
P_AAF44256    1141  CCAAGTGAAAAATCAGAGGCCACCTACATGACCATGCACCCAGTTTGGCCTTCTCTGAGG

ss.DNA68872   1201  TCAGATCGGAACAACTCACTTGAAAAAAAGTCAGGTGGGGGAATGCCAAAAACACAGCAA
                    ************************************************************
P_AAF44256    1201  TCAGATCGGAACAACTCACTTGAAAAAAAGTCAGGTGGGGGAATGCCAAAAACACAGCAA

ss.DNA68872   1261  GCCTTTTGAGAAGAATGGAGAGTCCCTTCATCTCAGCAGCGGTGGAGACTCTCTCCTGTG
                    ************************************************************
P_AAF44256    1261  GCCTTTTGAGAAGAATGGAGAGTCCCTTCATCTCAGCAGCGGTGGAGACTCTCTCCTGTG

ss.DNA68872   1321  TGTGTCCTGGGCCACTCTACCAGTGATTTCAGACTCCCGCTCTCCCAGCTGTCCTCCTGT
                    ************************************************************
P_AAF44256    1321  TGTGTCCTGGGCCACTCTACCAGTGATTTCAGACTCCCGCTCTCCCAGCTGTCCTCCTGT

ss.DNA68872   1381  CTCATTGTTTGGTCAATACACTGAAGATGGAGAATTTGGAGCCTGGCAGAGAGACTGGAC
                    ************************************************************
```

BLAST RESULTS A-2

BLAST RESULTS A-3

```
P_AAF44256  1381 CTCATTGTTTGGTCAATACACTGAAGATGGAGAATTTGGAGCCTGGCAGAGAGACTGGAC

ss.DNA68872 1441 AGCTCTGGAGGAACAGGCCTGCTGAGGGGAGGGGAGCATGGACTTGGCCTCTGGAGTGGG
                 ************************************************************
P_AAF44256  1441 AGCTCTGGAGGAACAGGCCTGCTGAGGGGAGGGGAGCATGGACTTGGCCTCTGGAGTGGG

ss.DNA68872 1501 ACACTGGCCCTGGGAACCAGGCTGAGCTGAGTGGCCTCAAACCCCCCGTTGGATCAGACC
                 ************************************************************
P_AAF44256  1501 ACACTGGCCCTGGGAACCAGGCTGAGCTGAGTGGCCTCAAACCCCCCGTTGGATCAGACC

ss.DNA68872 1561 CTCCTGTGGGCAGGGTTCTTAGTGGATGAGTTACTGGGAAGAATCAGAGATAAAAACCAA
                 ************************************************************
P_AAF44256  1561 CTCCTGTGGGCAGGGTTCTTAGTGGATGAGTTACTGGGAAGAATCAGAGATAAAAACCAA

ss.DNA68872 1621 CCCAAATCAA
                 **********
P_AAF44256  1621 CCCAAATCAA
```

>2 P_AAS21503 Human cDNA sequence encoding for PRO1387 polypeptide. (1630 bp) [1 seg]

```
 Score = 1630 (3231 bits), Expect = 0.0
 Identities = 1630/1630 (100%), at 1,1-1630,1630, Strand +/+

ss.DNA68872    1 CGGCTCGAGTGCAGCTGTGGGGAGATTTCAGTGCATTGCCTCCCCTGGGTGCTCTTCATC
                 ************************************************************
P_AAS21503     1 CGGCTCGAGTGCAGCTGTGGGGAGATTTCAGTGCATTGCCTCCCCTGGGTGCTCTTCATC

ss.DNA68872   61 TTGGATTTGAAAGTTGAGAGCAGCATGTTTTGCCCACTGAAACTCATCCTGCTGCCAGTG
                 ************************************************************
P_AAS21503    61 TTGGATTTGAAAGTTGAGAGCAGCATGTTTTGCCCACTGAAACTCATCCTGCTGCCAGTG

ss.DNA68872  121 TTACTGGATTATTCCTTGGGCCTGAATGACTTGAATGTTTCCCCGCCTGAGCTAACAGTC
                 ************************************************************
P_AAS21503   121 TTACTGGATTATTCCTTGGGCCTGAATGACTTGAATGTTTCCCCGCCTGAGCTAACAGTC

ss.DNA68872  181 CATGTGGGTGATTCAGCTCTGATGGGATGTGTTTTCCAGAGCACAGAAGACAAATGTATA
                 ************************************************************
P_AAS21503   181 CATGTGGGTGATTCAGCTCTGATGGGATGTGTTTTCCAGAGCACAGAAGACAAATGTATA

ss.DNA68872  241 TTCAAGATAGACTGGACTCTGTCACCAGGAGAGCACGCCAAGGACGAATATGTGCTATAC
                 ************************************************************
P_AAS21503   241 TTCAAGATAGACTGGACTCTGTCACCAGGAGAGCACGCCAAGGACGAATATGTGCTATAC

ss.DNA68872  301 TATTACTCCAATCTCAGTGTGCCTATTGGGCGCTTCCAGAACCGCGTACACTTGATGGGG
                 ************************************************************
P_AAS21503   301 TATTACTCCAATCTCAGTGTGCCTATTGGGCGCTTCCAGAACCGCGTACACTTGATGGGG

ss.DNA68872  361 GACATCTTATGCAATGATGGCTCTCTCCTGCTCCAAGATGTGCAAGAGGCTGACCAGGGA
                 ************************************************************
P_AAS21503   361 GACATCTTATGCAATGATGGCTCTCTCCTGCTCCAAGATGTGCAAGAGGCTGACCAGGGA

ss.DNA68872  421 ACCTATATCTGTGAAATCCGCCTCAAAGGGGAGAGCCAGGTGTTCAAGAAGGCGGTGGTA
                 ************************************************************
P_AAS21503   421 ACCTATATCTGTGAAATCCGCCTCAAAGGGGAGAGCCAGGTGTTCAAGAAGGCGGTGGTA

ss.DNA68872  481 CTGCATGTGCTTCCAGAGGAGCCCAAAGAGCTCATGGTCCATGTGGGTGGATTGATTCAG
                 ************************************************************
```

BLAST RESULTS A-4

```
P_AAS21503    481 CTGCATGTGCTTCCAGAGGAGCCCAAAGAGCTCATGGTCCATGTGGGTGGATTGATTCAG

ss.DNA68872   541 ATGGGATGTGTTTTCCAGAGCACAGAAGTGAAACACGTGACCAAGGTAGAATGGATATTT
                  ************************************************************
P_AAS21503    541 ATGGGATGTGTTTTCCAGAGCACAGAAGTGAAACACGTGACCAAGGTAGAATGGATATTT

ss.DNA68872   601 TCAGGACGGCGCGCAAAGGAGGAGATTGTATTTCGTTACTACCACAAACTCAGGATGTCT
                  ************************************************************
P_AAS21503    601 TCAGGACGGCGCGCAAAGGAGGAGATTGTATTTCGTTACTACCACAAACTCAGGATGTCT

ss.DNA68872   661 GTGGAGTACTCCCAGAGCTGGGGCCACTTCCAGAATCGTGTGAACCTGGTGGGGGACATT
                  ************************************************************
P_AAS21503    661 GTGGAGTACTCCCAGAGCTGGGGCCACTTCCAGAATCGTGTGAACCTGGTGGGGGACATT

ss.DNA68872   721 TTCCGCAATGACGGTTCCATCATGCTTCAAGGAGTGAGGGAGTCAGATGGAGGAAACTAC
                  ************************************************************
P_AAS21503    721 TTCCGCAATGACGGTTCCATCATGCTTCAAGGAGTGAGGGAGTCAGATGGAGGAAACTAC

ss.DNA68872   781 ACCTGCAGTATCCACCTAGGGAACCTGGTGTTCAAGAAAACCATTGTGCTGCATGTCAGC
                  ************************************************************
P_AAS21503    781 ACCTGCAGTATCCACCTAGGGAACCTGGTGTTCAAGAAAACCATTGTGCTGCATGTCAGC

ss.DNA68872   841 CCGGAAGAGCCTCGAACACTGGTGACCCCGGCAGCCCTGAGGCCTCTGGTCTTGGGTGGT
                  ************************************************************
P_AAS21503    841 CCGGAAGAGCCTCGAACACTGGTGACCCCGGCAGCCCTGAGGCCTCTGGTCTTGGGTGGT

ss.DNA68872   901 AATCAGTTGGTGATCATTGTGGGAATTGTCTGTGCCACAATCCTGCTGCTCCCTGTTCTG
                  ************************************************************
P_AAS21503    901 AATCAGTTGGTGATCATTGTGGGAATTGTCTGTGCCACAATCCTGCTGCTCCCTGTTCTG

ss.DNA68872   961 ATATTGATCGTGAAGAAGACCTGTGGAAATAAGAGTTCAGTGAATTCTACAGTCTTGGTG
                  ************************************************************
P_AAS21503    961 ATATTGATCGTGAAGAAGACCTGTGGAAATAAGAGTTCAGTGAATTCTACAGTCTTGGTG

ss.DNA68872  1021 AAGAACACGAAGAAGACTAATCCAGAGATAAAAGAAAAACCCTGCCATTTTGAAAGATGT
                  ************************************************************
P_AAS21503   1021 AAGAACACGAAGAAGACTAATCCAGAGATAAAAGAAAAACCCTGCCATTTTGAAAGATGT

ss.DNA68872  1081 GAAGGGGAGAAACACATTTACTCCCCAATAATTGTACGGGAGGTGATCGAGGAAGAAGAA
                  ************************************************************
P_AAS21503   1081 GAAGGGGAGAAACACATTTACTCCCCAATAATTGTACGGGAGGTGATCGAGGAAGAAGAA

ss.DNA68872  1141 CCAAGTGAAAAATCAGAGGCCACCTACATGACCATGCACCCAGTTTGGCCTTCTCTGAGG
                  ************************************************************
P_AAS21503   1141 CCAAGTGAAAAATCAGAGGCCACCTACATGACCATGCACCCAGTTTGGCCTTCTCTGAGG

ss.DNA68872  1201 TCAGATCGGAACAACTCACTTGAAAAAAAGTCAGGTGGGGGAATGCCAAAAACACAGCAA
                  ************************************************************
P_AAS21503   1201 TCAGATCGGAACAACTCACTTGAAAAAAAGTCAGGTGGGGGAATGCCAAAAACACAGCAA

ss.DNA68872  1261 GCCTTTTGAGAAGAATGGAGAGTCCCTTCATCTCAGCAGCGGTGGAGACTCTCTCCTGTG
                  ************************************************************
P_AAS21503   1261 GCCTTTTGAGAAGAATGGAGAGTCCCTTCATCTCAGCAGCGGTGGAGACTCTCTCCTGTG

ss.DNA68872  1321 TGTGTCCTGGGCCACTCTACCAGTGATTTCAGACTCCCGCTCTCCCAGCTGTCCTCCTGT
                  ************************************************************
P_AAS21503   1321 TGTGTCCTGGGCCACTCTACCAGTGATTTCAGACTCCCGCTCTCCCAGCTGTCCTCCTGT
```

BLAST RESULTS A-5

```
ss.DNA68872 1381 CTCATTGTTTGGTCAATACACTGAAGATGGAGAATTTGGAGCCTGGCAGAGAGACTGGAC
                 ************************************************************
P_AAS21503  1381 CTCATTGTTTGGTCAATACACTGAAGATGGAGAATTTGGAGCCTGGCAGAGAGACTGGAC

ss.DNA68872 1441 AGCTCTGGAGGAACAGGCCTGCTGAGGGGAGGGGAGCATGGACTTGGCCTCTGGAGTGGG
                 ************************************************************
P_AAS21503  1441 AGCTCTGGAGGAACAGGCCTGCTGAGGGGAGGGGAGCATGGACTTGGCCTCTGGAGTGGG

ss.DNA68872 1501 ACACTGGCCCTGGGAACCAGGCTGAGCTGAGTGGCCTCAAACCCCCCGTTGGATCAGACC
                 ************************************************************
P_AAS21503  1501 ACACTGGCCCTGGGAACCAGGCTGAGCTGAGTGGCCTCAAACCCCCCGTTGGATCAGACC

ss.DNA68872 1561 CTCCTGTGGGCAGGGTTCTTAGTGGATGAGTTACTGGGAAGAATCAGAGATAAAAACCAA
                 ************************************************************
P_AAS21503  1561 CTCCTGTGGGCAGGGTTCTTAGTGGATGAGTTACTGGGAAGAATCAGAGATAAAAACCAA

ss.DNA68872 1621 CCCAAATCAA
                 **********
P_AAS21503  1621 CCCAAATCAA
```

>3 P_AAZ65110 Membrane-bound protein PRO1387 encoding cDNA. (1630 bp) [1 seg]
Score = 1630 (3231 bits), Expect = 0.0
Identities = 1630/1630 (100%), at 1,1-1630,1630, Strand +/+

```
ss.DNA68872    1 CGGCTCGAGTGCAGCTGTGGGGAGATTTCAGTGCATTGCCTCCCCTGGGTGCTCTTCATC
                 ************************************************************
P_AAZ65110     1 CGGCTCGAGTGCAGCTGTGGGGAGATTTCAGTGCATTGCCTCCCCTGGGTGCTCTTCATC

ss.DNA68872   61 TTGGATTTGAAAGTTGAGAGCAGCATGTTTTGCCCACTGAAACTCATCCTGCTGCCAGTG
                 ************************************************************
P_AAZ65110    61 TTGGATTTGAAAGTTGAGAGCAGCATGTTTTGCCCACTGAAACTCATCCTGCTGCCAGTG

ss.DNA68872  121 TTACTGGATTATTCCTTGGGCCTGAATGACTTGAATGTTTCCCCGCCTGAGCTAACAGTC
                 ************************************************************
P_AAZ65110   121 TTACTGGATTATTCCTTGGGCCTGAATGACTTGAATGTTTCCCCGCCTGAGCTAACAGTC

ss.DNA68872  181 CATGTGGGTGATTCAGCTCTGATGGGATGTGTTTTCCAGAGCACAGAAGACAAATGTATA
                 ************************************************************
P_AAZ65110   181 CATGTGGGTGATTCAGCTCTGATGGGATGTGTTTTCCAGAGCACAGAAGACAAATGTATA

ss.DNA68872  241 TTCAAGATAGACTGGACTCTGTCACCAGGAGAGCACGCCAAGGACGAATATGTGCTATAC
                 ************************************************************
P_AAZ65110   241 TTCAAGATAGACTGGACTCTGTCACCAGGAGAGCACGCCAAGGACGAATATGTGCTATAC

ss.DNA68872  301 TATTACTCCAATCTCAGTGTGCCTATTGGGCGCTTCCAGAACCGCGTACACTTGATGGGG
                 ************************************************************
P_AAZ65110   301 TATTACTCCAATCTCAGTGTGCCTATTGGGCGCTTCCAGAACCGCGTACACTTGATGGGG

ss.DNA68872  361 GACATCTTATGCAATGATGGCTCTCTCCTGCTCCAAGATGTGCAAGAGGCTGACCAGGGA
                 ************************************************************
P_AAZ65110   361 GACATCTTATGCAATGATGGCTCTCTCCTGCTCCAAGATGTGCAAGAGGCTGACCAGGGA

ss.DNA68872  421 ACCTATATCTGTGAAATCCGCCTCAAAGGGGAGAGCCAGGTGTTCAAGAAGGCGGTGGTA
                 ************************************************************
P_AAZ65110   421 ACCTATATCTGTGAAATCCGCCTCAAAGGGGAGAGCCAGGTGTTCAAGAAGGCGGTGGTA
```

BLAST RESULTS A-9

```
ss.DNA68872   481 CTGCATGTGCTTCCAGAGGAGCCCAAAGAGCTCATGGTCCATGTGGGTGGATTGATTCAG
                 ************************************************************
P_AAZ65110    481 CTGCATGTGCTTCCAGAGGAGCCCAAAGAGCTCATGGTCCATGTGGGTGGATTGATTCAG

ss.DNA68872   541 ATGGGATGTGTTTTCCAGAGCACAGAAGTGAAACACGTGACCAAGGTAGAATGGATATTT
                 ************************************************************
P_AAZ65110    541 ATGGGATGTGTTTTCCAGAGCACAGAAGTGAAACACGTGACCAAGGTAGAATGGATATTT

ss.DNA68872   601 TCAGGACGGCGCGCAAAGGAGGAGATTGTATTTCGTTACTACCACAAACTCAGGATGTCT
                 ************************************************************
P_AAZ65110    601 TCAGGACGGCGCGCAAAGGAGGAGATTGTATTTCGTTACTACCACAAACTCAGGATGTCT

ss.DNA68872   661 GTGGAGTACTCCCAGAGCTGGGGCCACTTCCAGAATCGTGTGAACCTGGTGGGGGACATT
                 ************************************************************
P_AAZ65110    661 GTGGAGTACTCCCAGAGCTGGGGCCACTTCCAGAATCGTGTGAACCTGGTGGGGGACATT

ss.DNA68872   721 TTCCGCAATGACGGTTCCATCATGCTTCAAGGAGTGAGGGAGTCAGATGGAGGAAACTAC
                 ************************************************************
P_AAZ65110    721 TTCCGCAATGACGGTTCCATCATGCTTCAAGGAGTGAGGGAGTCAGATGGAGGAAACTAC

ss.DNA68872   781 ACCTGCAGTATCCACCTAGGGAACCTGGTGTTCAAGAAAACCATTGTGCTGCATGTCAGC
                 ************************************************************
P_AAZ65110    781 ACCTGCAGTATCCACCTAGGGAACCTGGTGTTCAAGAAAACCATTGTGCTGCATGTCAGC

ss.DNA68872   841 CCGGAAGAGCCTCGAACACTGGTGACCCCGGCAGCCCTGAGGCCTCTGGTCTTGGGTGGT
                 ************************************************************
P_AAZ65110    841 CCGGAAGAGCCTCGAACACTGGTGACCCCGGCAGCCCTGAGGCCTCTGGTCTTGGGTGGT

ss.DNA68872   901 AATCAGTTGGTGATCATTGTGGGAATTGTCTGTGCCACAATCCTGCTGCTCCCTGTTCTG
                 ************************************************************
P_AAZ65110    901 AATCAGTTGGTGATCATTGTGGGAATTGTCTGTGCCACAATCCTGCTGCTCCCTGTTCTG

ss.DNA68872   961 ATATTGATCGTGAAGAAGACCTGTGGAAATAAGAGTTCAGTGAATTCTACAGTCTTGGTG
                 ************************************************************
P_AAZ65110    961 ATATTGATCGTGAAGAAGACCTGTGGAAATAAGAGTTCAGTGAATTCTACAGTCTTGGTG

ss.DNA68872  1021 AAGAACACGAAGAAGACTAATCCAGAGATAAAAGAAAAACCCTGCCATTTTGAAAGATGT
                 ************************************************************
P_AAZ65110   1021 AAGAACACGAAGAAGACTAATCCAGAGATAAAAGAAAAACCCTGCCATTTTGAAAGATGT

ss.DNA68872  1081 GAAGGGGAGAAACACATTTACTCCCCAATAATTGTACGGGAGGTGATCGAGGAAGAAGAA
```